Pembrolizumab berahyaluronidase alfa vs Penpulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT05722015 · Phase 3 · active, not recruiting
Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.
Next expected readout: December 2029 · NCT07190248 (registry estimate)
Reported efficacy
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)
Result source: NCT05722015
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Pembrolizumab berahyaluronidase alfa | Penpulimab |
|---|---|---|
| PFS, median | —Trial running · NCT05722015 | 8.6 vs 4.2a+4.4 vs placeboNCT03866993 |
| OS, median | —Trial running · NCT05722015 | —Not posted · NCT03866993 |
| ORR | 64.3% vs 18.2%vs PembrolizumabNCT06212752 | —Not posted · NCT03866993 |
| Duration of response, median | —Trial running · NCT05722015 | —Not posted · NCT03866993 |
PFS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
OS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Penpulimab
- —Not posted · NCT03866993
ORR
- Pembrolizumab berahyaluronidase alfa
- 64.3% vs 18.2%vs PembrolizumabNCT06212752
- Penpulimab
- —Not posted · NCT03866993
Duration of response, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Penpulimab
- —Not posted · NCT03866993
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Pembrolizumab berahyaluronidase alfa: 2 of 4 rows · Penpulimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pembrolizumab berahyaluronidase alfa | Penpulimab |
|---|---|---|
| Dropout rate | n/a: no completion milestonea NCT05722015 · Phase 3 · combination show 1 more resultn/a: no completion milestone NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | — |
| Discontinued due to AEs | —a NCT05722015 · Phase 3 · combination show 1 more result— NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | — |
| Serious AEs | 39%a NCT05722015 · Phase 3 · combination show 1 more result42.9% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | — |
| Most frequent reported AEs | show 1 more resultneutropenia 46.4% anaemia 42.9% constipation 39.3% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | — |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab berahyaluronidase alfa
Penpulimab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab berahyaluronidase alfa's landscape · Penpulimab's landscape